Clinical Trials Brief | April 6, 2026
This week's five signals cover new EU guidance for running clinical trials during public health emergencies, an FDA push to remove unnecessary biosimilar-development work, an EMA move toward a more tailored biosimilar evidence model, an important Ixchiq safety clarification from PRAC, and a new Tempus-Daiichi Sankyo collaboration focused on biomarker discovery and smarter patient selection.
Europe is trying to make emergency trial activation less improvised next time
What changed
ACT EU published draft guidance on the conduct of clinical trials during public health emergencies in the EU, with consultation open through April 30, 2026.
Why it matters
The guidance shows regulators trying to make faster authorization, faster modifications, and better trial continuity part of the operating model rather than an emergency exception.
Takeaway
The deeper signal is trial-readiness. Systems are being redesigned so speed under pressure becomes more repeatable and less improvised.
FDA is still cutting unnecessary work out of biosimilar development
What changed
FDA recommended streamlining certain unnecessary comparative clinical pharmacokinetic testing in biosimilar development when scientifically justified.
Why it matters
This is an operational signal that FDA is removing study work that may add cost and time without proportionate decision value.
Takeaway
The more important story is not only affordability. It is that evidence requirements are being pushed toward greater precision and less ritual.
EMA is also moving toward a more tailored biosimilar evidence model
What changed
In meeting highlights from March 23-26, 2026, EMA said CHMP adopted a reflection paper on a tailored clinical approach in biosimilar development.
Why it matters
Together with recent FDA moves, this suggests a broader shift toward better-targeted evidence rather than automatic reliance on older development habits.
Takeaway
Regulators appear increasingly willing to remove evidence requirements that do not clearly improve decision quality.
PRAC broadened the risk context for Ixchiq
IXCHIQ (VLA1553) is the first licensed, live-attenuated vaccine used to protect adults (18+) against the chikungunya virus, a mosquito-borne illness causing severe, long-term joint pain. Approved in the US, Canada, and Europe, it is administered as a single dose.
What changed
EMA said serious side effects such as aseptic meningitis had also been observed in healthy young adults, not only in older adults or people with multiple long-term medical conditions.
Why it matters
The key issue is not only that the risk exists, but that the profile of affected patients now looks broader than before.
Takeaway
Safety interpretation changes when the population context changes, even if the product's overall status does not dramatically shift.
Tempus and Daiichi Sankyo are using multimodal AI to make patient selection more explicit
What changed
Tempus said the collaboration combines multimodal AI, real-world oncology data, and program-specific clinical and preclinical data to support biomarker discovery and clinical differentiation across an ADC program.
Why it matters
This is a concrete development signal because it focuses on patient selection and strategic trial design rather than generic claims about AI in pharma.
Takeaway
The near-term AI opportunity still looks more like sharper trial populations and biomarker strategy than wholesale replacement of evidence generation.